Clinical Trials Logo

Filter by:
NCT ID: NCT05120375 Terminated - Solid Tumor Clinical Trials

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China

Start date: February 17, 2022
Phase: Phase 1
Study type: Interventional

Main purpose: - To evaluate the safety and tolerability of BAT6021 injection in the treatment of locally advanced or metastatic solid tumors with single drug or combined with tislelizumab(anti PD-1 monoclonal antibody); - Explore the maximum tolerated dose (MTD) or maximum dosing dose (MAD) of BAT6021 injection monotherapy or in combination with tislelizumab and provide recommended dose and reasonable dosing regimen for phase II or subsequent clinical studies. Secondary purpose: - To evaluate the pharmacokinetic (PK) characteristics of BAT6021 injection with single or multiple doses of tislelizumab in patients with locally advanced or metastatic solid tumors; - Evaluate the immunogenicity of BAT6021 injection; - To evaluate the pharmacodynamics of BAT6021 injection; - Preliminary evaluation of the anti-tumor efficacy of BAT6021 injection alone or in combination with tislelizumab.

NCT ID: NCT05106335 Terminated - Advanced NSCLC Clinical Trials

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Start date: January 6, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.

NCT ID: NCT05103826 Terminated - Clinical trials for ER+ / HER2- Advanced Breast Cancer

A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

Start date: October 25, 2021
Phase: Phase 1
Study type: Interventional

The study is being conducted to assess the safety 、tolerability 、 pharmacokinetics and efficacy of SHR6390 combined with famitinib in the treatment of ER + / HER2- advanced breast cancer.

NCT ID: NCT05101668 Terminated - Clinical trials for Acute Ischemic Stroke

Safety and Efficacy of Intracranial Thrombus Aspiration Catheter in the Treatment of Acute Large-vessel Occlusive Stroke

Start date: October 8, 2021
Phase: N/A
Study type: Interventional

A prospective, multicenter, single-arm objective performance criteria trial to investigate the safety and efficacy of SINOMED ADPAT for Recanalization Therapy in acute large-vessel occlusive stroke.

NCT ID: NCT05088967 Terminated - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Start date: December 2, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the neoadjuvant therapy efficacy of IBI110 in combination with sintilimab versus sintilimab alone based on pathologic complete response (pCR) rate in stage IIB (primary tumor > 4 cm ) to IIIB (N2 only) subjects with radically resectable NSCLC.

NCT ID: NCT05075304 Terminated - COVID-19 Clinical Trials

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

Start date: February 21, 2020
Phase: Phase 1
Study type: Interventional

This open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and PK/PD of BDB-001 injection in patients with mild, or general COVID-19.

NCT ID: NCT05056727 Terminated - Clinical trials for Renal Insufficiency, Chronic

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

STABILIZE-CKD
Start date: September 30, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's glomerular filtration rate [eGFR] decline over time) in participants with hyperkalaemia or at high risk of hyperkalaemia.

NCT ID: NCT05049096 Terminated - Hypertension Clinical Trials

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension

PARADISE-HTN
Start date: November 1, 2021
Phase: N/A
Study type: Interventional

This randomized, double blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.

NCT ID: NCT05039944 Terminated - Colorectal Cancer Clinical Trials

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Start date: November 30, 2021
Phase: Phase 2
Study type: Interventional

This multi-center, open label Phase II clinical study is performed in patients with unresectable or metastatic malignant tumors of the digestive system (colorectal cancer, gastric cancer). This study is investigating the safety and efficacy of SI-B001 at monotherapy or optimal combination dose with chemotherapy in patients.

NCT ID: NCT05017233 Terminated - CT Scanning Clinical Trials

Spectral CT Clinical Trial Protocol

Start date: July 4, 2022
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate the expected effectiveness, ease of operation, stability, and safety of Spectral CT